Alzheimer's Disease Clinical Trials in San Francisco, CA

29 recruiting studies within 50 miles

Phase
Trial Phase Dist.
Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project—<1 mi
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy VolunteersPhase 1/2<1 mi
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in DementiaPhase 1/2<1 mi
Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183AEarly 1<1 mi
[18F]PI-2620 Phase 3 Histopathological StudyPhase 3<1 mi
Remotely-supervised Neuromodulation in PPAN/A<1 mi
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseasePhase 3<1 mi
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantPhase 3<1 mi
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)Phase 2<1 mi
A Study of Psychedelics in Healthy Older Adults With Low Well-beingPhase 1<1 mi
Alzheimer's Tau Platform: Master ProtocolPhase 2<1 mi
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease StudiesPhase 38 mi
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseasePhase 38 mi
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's DiseasePhase 28 mi
Computerized Tests of Cognitive Decline in Presymptomatic Alzheimer's DiseaseN/A10 mi
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's DiseasePhase 221 mi
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)Phase 321 mi
Senicapoc in Alzheimer's DiseasePhase 221 mi
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)Phase 321 mi
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)Phase 321 mi
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)Phase 321 mi
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)Phase 321 mi
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).Phase 321 mi
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)Phase 328 mi
Robotic-Enabled Microsurgical Intervention for Neurodegenerative DiseaseN/A28 mi
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)Phase 228 mi
Bumetanide in Patients With Alzheimer's DiseasePhase 228 mi
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's DiseasePhase 337 mi
Caring Recharge Project for Caregivers of Individuals With Alzheimer's DiseasePhase 242 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.